[
  {
    "ts": null,
    "headline": "Johnson & Johnson’s (JNJ) Strong Dividend Track Record and Focus on Innovation",
    "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 12 Reliable Dividend Stocks for Maximum Income. Johnson & Johnson (NYSE:JNJ) operates as a global healthcare lea‍de‌r, focusing p‌rimari​ly on pharmaceuticals and medi⁠cal d‍evices. Its⁠ operations are di‍vided into two main se⁠gment​s: Innovative Me⁠dicine, which de⁠velops and markets prescription drugs, and MedTech, which produces medi⁠cal d‌evic‌es. Up […]",
    "url": "https://finnhub.io/api/news?id=b79ea772c3b442c0d2b931c5944941550fccf92c774cabe83d8742a04d937629",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760467311,
      "headline": "Johnson & Johnson’s (JNJ) Strong Dividend Track Record and Focus on Innovation",
      "id": 137085555,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "KVUE",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 12 Reliable Dividend Stocks for Maximum Income. Johnson & Johnson (NYSE:JNJ) operates as a global healthcare lea‍de‌r, focusing p‌rimari​ly on pharmaceuticals and medi⁠cal d‍evices. Its⁠ operations are di‍vided into two main se⁠gment​s: Innovative Me⁠dicine, which de⁠velops and markets prescription drugs, and MedTech, which produces medi⁠cal d‌evic‌es. Up […]",
      "url": "https://finnhub.io/api/news?id=b79ea772c3b442c0d2b931c5944941550fccf92c774cabe83d8742a04d937629"
    }
  },
  {
    "ts": null,
    "headline": "Albert Invent Partners with Kenvue to Build the Future of Consumer Health Products With the Help of AI",
    "summary": "SUMMIT, N.J. & OAKLAND, Calif., October 14, 2025--Frontier AI company Albert Invent today announced a strategic partnership with Kenvue Inc. (NYSE: KVUE), maker of consumer health products like Zyrtec®, Neutrogena®, and Listerine®, to accelerate end-to-end R&D efforts across the company’s global portfolio of brands. The partnership enables Kenvue to streamline, digitalize, and accelerate the end-to-end product lifecycle by leveraging Albert Invent's foundational AI models.",
    "url": "https://finnhub.io/api/news?id=e769e1ddc3bb3f557c4cca2ce56af03f42f2bf6b2bf08dedc75c72657378934a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760457600,
      "headline": "Albert Invent Partners with Kenvue to Build the Future of Consumer Health Products With the Help of AI",
      "id": 137086321,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "KVUE",
      "source": "Yahoo",
      "summary": "SUMMIT, N.J. & OAKLAND, Calif., October 14, 2025--Frontier AI company Albert Invent today announced a strategic partnership with Kenvue Inc. (NYSE: KVUE), maker of consumer health products like Zyrtec®, Neutrogena®, and Listerine®, to accelerate end-to-end R&D efforts across the company’s global portfolio of brands. The partnership enables Kenvue to streamline, digitalize, and accelerate the end-to-end product lifecycle by leveraging Albert Invent's foundational AI models.",
      "url": "https://finnhub.io/api/news?id=e769e1ddc3bb3f557c4cca2ce56af03f42f2bf6b2bf08dedc75c72657378934a"
    }
  },
  {
    "ts": null,
    "headline": "J&J lays out plan to splinter orthopedics business into separate company",
    "summary": "Johnson & Johnson is narrowing its focus again, nearly four years after peeling off its consumer health business.  The health care giant said Tuesday that it will separate its orthopedics business into a standalone company known as DePuy Synthes.  The move leaves J&J focused on its pharmaceutical and MedTech segments, which make prescription drugs, contact lenses and technology to treat cardiovascular disease and help with surgeries.",
    "url": "https://finnhub.io/api/news?id=2fd447fc479d9c4b09a482a17dbe345905c5258820f7452d2f73b0018b5d5216",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760448035,
      "headline": "J&J lays out plan to splinter orthopedics business into separate company",
      "id": 137086322,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "KVUE",
      "source": "Yahoo",
      "summary": "Johnson & Johnson is narrowing its focus again, nearly four years after peeling off its consumer health business.  The health care giant said Tuesday that it will separate its orthopedics business into a standalone company known as DePuy Synthes.  The move leaves J&J focused on its pharmaceutical and MedTech segments, which make prescription drugs, contact lenses and technology to treat cardiovascular disease and help with surgeries.",
      "url": "https://finnhub.io/api/news?id=2fd447fc479d9c4b09a482a17dbe345905c5258820f7452d2f73b0018b5d5216"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Earnings Beat Estimates. Why the Stock Is Dropping.",
    "summary": "Johnson & Johnson  reported better-than-expected earnings Tuesday, while announcing it would spin off a slower-growing division within its medical devices segment that makes hip and knee implants.  Now, Johnson & Johnson plans to separate that business into a new company that will operate under the name DePuy Synthes.  While sales for Johnson & Johnson’s medical devices division grew 5.6% on an operational basis between the third quarter of 2024 and the third quarter of 2025, orthopaedics sales grew more slowly, up just 2.4% over the same period.",
    "url": "https://finnhub.io/api/news?id=37f99b90fa6df76efe96e4bfb5786b7fb24f9c238e23a603857d0f7a40cf88bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760445780,
      "headline": "Johnson & Johnson Earnings Beat Estimates. Why the Stock Is Dropping.",
      "id": 137085947,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "KVUE",
      "source": "Yahoo",
      "summary": "Johnson & Johnson  reported better-than-expected earnings Tuesday, while announcing it would spin off a slower-growing division within its medical devices segment that makes hip and knee implants.  Now, Johnson & Johnson plans to separate that business into a new company that will operate under the name DePuy Synthes.  While sales for Johnson & Johnson’s medical devices division grew 5.6% on an operational basis between the third quarter of 2024 and the third quarter of 2025, orthopaedics sales grew more slowly, up just 2.4% over the same period.",
      "url": "https://finnhub.io/api/news?id=37f99b90fa6df76efe96e4bfb5786b7fb24f9c238e23a603857d0f7a40cf88bf"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson’s stock heads for a record after a profit beat and plans for another spinoff",
    "summary": "Johnson & Johnson’s stock heads for a record after a profit beat and plans for another spinoff",
    "url": "https://finnhub.io/api/news?id=a3216370351a86412c496ec5b40c6b577eefe88bae75729c79703670d6ce0a88",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760427840,
      "headline": "Johnson & Johnson’s stock heads for a record after a profit beat and plans for another spinoff",
      "id": 137136655,
      "image": "",
      "related": "KVUE",
      "source": "MarketWatch",
      "summary": "Johnson & Johnson’s stock heads for a record after a profit beat and plans for another spinoff",
      "url": "https://finnhub.io/api/news?id=a3216370351a86412c496ec5b40c6b577eefe88bae75729c79703670d6ce0a88"
    }
  }
]